Contact
233 S. 10th Street
Philadelphia, PA 19107
Highlighted Publications
Capparelli C*, Purwin TJ, Tiago M, Wilski N, Caksa S, Glasheen MK, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, Rebecca VW, Snook AE, Hookim K, Xu X, Cukierman E, Herlyn M, Aplin AE *. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Commun. 2022 16;13(1):1381 PMID: 35296667. (*Co-corresponding author)
Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021;37(10):110085. PMID: 34879275.
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 targeting enhances MEK inhibitor effects in wild-type BRAF/NRAS melanoma. Cancer Res. 2018;78(19):5680-5693. PMID: 30115691; PMCID: PMC6168374
Capparelli C, Rosenbaum S, Berger AC, Aplin AE. Fibroblast-derived neuregulin-1 promotes compensatory ErbB3 signaling in mutant BRAF melanoma. J Biol Chem. 2015;290(40):24267-77. PMID: 26269601; PMCID: PMC4591813
Capparelli C, Rosenbaum S, Berman-Booty LD, Gaborit N, Zhan T, Davies MA, Setiady YY, Yarden Y, Aplin AE. ErbB3-ErbB2 complexes as a therapeutic target in a subset or wild-type BRAF/NRAS cutaneous melanomas. Cancer Res. 2015;75(17):3554-67. PMID: 26206558
Publications
- SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death
- Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas
- Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma
- MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping
- Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
- Packing a Punch against PD-L1
- SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
- Combined SHPments: An Effective Therapeutic Strategy for MPNST
- Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
- The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner
- ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma
- TP53-inducible glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancer
- MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma
- Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
- ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
- Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation
- CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis
- Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: Connecting TGF-β signaling with "Warburg- like" cancer metabolism and L-lactate production
- Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production
- CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth